CAPLIPOINT vs LASA: Stock Comparison

Caplin Point Laboratories Limited vs Lasa Supergenerics Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Caplin Point Laboratories Limited is the larger company by market capitalisation. Caplin Point Laboratories Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Caplin Point Laboratories Limited and Lasa Supergenerics Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CAPLIPOINT is more favourable on 11 of 11 scored metrics and LASA on 0These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CAPLIPOINT is the larger company
₹18,839 Cr vs ₹36 Cr
EPS
CAPLIPOINT has higher earnings per share
₹83.98 vs ₹-6.8
Dividend Yield
CAPLIPOINT has a higher dividend yield
0.3% vs 0%
Revenue Growth (TTM YoY)
CAPLIPOINT has faster revenue growth
19% vs 0%
EPS Growth (TTM YoY)
CAPLIPOINT has faster EPS growth
19.4% vs 0%
Qtr Sales Growth
CAPLIPOINT has stronger quarterly sales growth
19.4% vs -100%
Qtr Profit Growth
CAPLIPOINT has stronger quarterly profit growth
19.3% vs -139%
ROE
CAPLIPOINT has a higher ROE
20.6% vs -19.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCAPLIPOINTLASA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCAPLIPOINTLASA
Live Price₹2,483.9₹7.11
Day Change-4.76%-2.6%
Volume1.65 L13,146
52-Week High₹2,699₹14.08
52-Week Low₹1,500.3₹5.67
Distance from 52W High-7.97%-49.5%

Valuation

MetricCAPLIPOINTLASA
Market Cap₹18,839 Cr₹36 Cr
P/E Ratio31.01x
P/B Ratio5.54x
EPS₹83.98₹-6.8
Book Value₹462.02₹9.89
Dividend Yield0.3%0%

Growth

MetricCAPLIPOINTLASA
Revenue Growth (TTM YoY)19%0%
EPS Growth (TTM YoY)19.4%0%
Qtr Sales Growth19.4%-100%
Qtr Profit Growth19.3%-139%

Profitability & Leverage

MetricCAPLIPOINTLASA
ROE20.6%-19.6%
ROCE24.6%-18.2%
Net Margin29.2%-135.6%
Operating Margin34.8%-29.3%
Debt to Equity0x0.2x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCAPLIPOINTLASA
Promoter Holding70.57%53.65%
FII Holding6.15% 0.44 pp0%
DII Holding2.14% 0.09 pp0%
Public Holding21.14% 0.35 pp46.35%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Caplin Point Laboratories Limited and Lasa Supergenerics Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.